Currently, ICI-AIN is treated by holding or discontinuing ICIs and administering glucocorticoids, which may compromise anti-tumor immune response.38,39 Drugs targeting IFNγ and its receptors, and especially drugs such as baricitinib and ruloxitinib—which target the downstream signaling of JAK/STAT—may thus have greater utility in treating ICI-AIN. This evidence concerns the gene SOAT1 and neoplasm.